Abstract:Cancer is a serious threat to human life and health. It has become the leading cause of death worldwide. According to the National Cancer Center 2019 National Cancer Report, there were about 4 million new cases of cancer in China in 2015, and 8 people were diagnosed with cancer and 5 people died of cancer every minute. Currently, cancer remains a major threat to human health in China and is associated with a high mortality rate. While great efforts have been devoted to the development of cancer therapies, including surgery, radiotherapy, chemotherapy, traditional Chinese medicine, targeted therapy, and immunotherapy, most cancer therapies fail to achieve satisfactory efficacy, which is closely related to the lack of understanding of tumors in modern science, absence of major breakthroughs in the field of cancer research using key cutting-edge technologies, and limited translation and application of the achievements of basic research findings. Cancer represents a collection of multi-origin and multi-step systemic chronic diseases with various outcomes. The high heterogeneity of cancer poses a challenge for traditional therapeutic approaches to treat one type of tumor with the same method but provides opportunities to promote personalized therapies, including immunotherapy and targeted therapy. To promote original and innovative cancer research in China, it is essential to take advantage of modern genetic technology, stem cell technology, molecular imaging technology, molecular diagnosis, bioinformatics, innovative drug development, physical and chemical research methods, and alternative cutting-edge technologies, combined with extensive clinical data and patient population in China. For these reasons, the National Natural Science Foundation of China organized the 223rd Shuangqing Forum titled “Cancer Research Driven by Cutting-edge Multi-disciplinary Technologies”. Forty-five scholars from more than 30 universities and research institutes in China were invited to participate in this forum, and summarized the current status and trend in cancer research, especially the role of cutting-edge technologies in promoting cancer research, the key future research directions, and key scientific challenges. Based on the discussion of forum participants, this review highlights the current status, progress, challenges, and opportunities of cancer research in China, and presents the achievement and importance of multi-disciplinary technologies in driving cancer research and developing cancer therapy and diagnostics. It also summarizes the key scientific questions in the cancer research field for the next 5 to 10 years, and proposes strategies to fund cutting-edge technologies in exploring cancer research in China.

Targeting rare tumors: new focus for clinical research in China.

Rare tumors: a blue ocean of investigation

First report: PLATFORM Study for precision treatment of Rare Tumors in China

Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy

The Prevalence of Targetable Genomic Alterations is Substantially High in Rare Tumors.

A Call for Innovative Translational and Clinical Research to Address China's Unique Cancer Landscape

Targeted Therapy for Intractable Cancer on the Basis of Molecular Profiles: an Open-Label, Phase II Basket Trial (long March Pathway)

Growing research and development of targeted anticancer drugs in China

The Burden of Rare Tumors in China: Results of a Population-Study

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Analysis ofclinical trials of rare disease drugsin China and abroad

Research progress of rare lung cancers

Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview

New Platform for Collecting Real-World Data on Directing Clinical Trial Optimization, Especially for Rare Mutations in Lung Cancer.

Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors

Comprehensive genomic profiling of MET rare tumors in China.

Cancer research driven by cutting-edge multi-disciplinary technologies

An overview of innovative cancer drug clinical development in China

Ott_a_230309 10343..10360